[Zhou Jun] the "earthquake" hit the drug market; the issuance of drug "ID card" is imminent; with the deepening of anti-corruption, bribery will face the risk of "out of the game"; remote examination, starting from chain drugstores

This week's highlights: 1 The "earthquake" in the drug market, and the "alarm" of rational drug use by the drug administration; 2 Until you finally, the drug "ID card" will be issued soon; 3 The deepening of drug anti-corruption, bribery will face "out"; 4 Remote audit, starting from the chain drugstore The State Administration has heard about the "earthquake" coming from the drug market, and the drug administration has been constantly alerted about rational drug use On the evening of July 1, the general office of the National Health Commission and the office of the State Administration of traditional Chinese medicine officially issued the notice on printing and distributing the first batch of national key monitoring and rational drug catalog (chemical and biological products) (hereinafter referred to as the "notice"), and 20 kinds of drugs, such as ganglioside, cerebrosigmosin and oxiracetam, were included in the first batch of catalog According to the notice, each medical institution shall establish a management system for monitoring the rational use of drugs and strengthen the whole process management of the clinical application of drugs in the catalogue There are several points worthy of attention: ① all of the above 20 drugs are chemical and biological products, including 11 drugs for the treatment of nervous system diseases, accounting for more than 50% Many of them are varieties that have appeared in the local monitored catalogue before, just as olacetam is called neuroprotective agent, but it lacks high-quality clinical evidence If it is used in large quantities, there is no doubt that it is unreasonable to restrict its use nationwide ② There are 172 enterprises involved in the 20 restricted varieties, more than 20 of which are listed companies, with a total market size of 47.5 billion yuan (based on sales volume in 2018) The most affected one is Sihuan pharmaceutical under Sihuan pharmaceutical, with a total of 7 products entering the catalog ③ It is an important safeguard measure to strengthen the clinical application management of auxiliary drugs in medical institutions, standardize the clinical application behavior of auxiliary drugs, improve the level of rational use of drugs, and safeguard the health rights and interests of the people ④ The first batch of national key monitoring and rational use of drugs does not include traditional Chinese medicine injection, but the prescription management of traditional Chinese medicine is required, and it is clear that only qualified doctors can issue prescriptions In theory, more than 70% of Chinese patent medicines will be banned from western medicine If Western medicine is explicitly prohibited from issuing Chinese patent medicines and traditional Chinese medicine injections, Chinese medicine manufacturers will inevitably face a collapse ⑤ The fuse function, the national version of the directory only plays a leading role at present, and 20 varieties play a limited role In the next step, the relevant provinces are required to issue the provincial version of the directory After the provincial version of the directory is issued, all kinds of medical institutions at all levels are required to form the hospital version of the directory on this basis, and later there is "supplement" behavior ⑥ "On the list" the clinical use of drugs is linked to performance, which also conveys the pressure to the front-line medical institutions For the varieties with unreasonable drug use problems, measures such as ranking notification, rectification within a time limit, clearing out the drug supply catalogue of this institution are taken to ensure rational drug use ⑦ In addition, for the drugs out of the catalog, the bureau also stressed that the prescription management of drugs out of the catalog should be strengthened, and the doctors should strictly follow the indications, disease diagnosis and treatment standard guidelines and the corresponding prescription authority specified in the drug manual, and reasonably select the drug varieties, drug delivery routes and dosage and issue a prescription The spirit of the policy makers is clear at a glance, that is, after the monitoring directory is officially issued, there is no grey space for medical institutions and doctors in clinical use, which will affect the construction of sales teams of some enterprises, and then the layoff trend of medical representatives may come early Finally, on June 27, when the drug "ID card" was issued, the state health insurance bureau issued the guiding opinions on the standardization of medical insurance (hereinafter referred to as the "guiding opinions"), which called for accelerating the formation of a unified national medical insurance standardization system, so as to improve the operation quality and decision-making management level of medical insurance business, and play the supporting and leading role of information standardization in medical insurance management On the same day, the state health insurance bureau also issued the notice on information maintenance of Medicare drugs and medical consumables, which requires the approved drugs and consumables enterprises before June 30 to report their product codes by September 30, and the drugs and consumables usher in the first step of reform In the future, medical insurance disease diagnosis, operation classification and code, medical insurance drug classification and code, medical insurance consumables classification and code, medical insurance system unit classification and code, medical insurance system staff code, designated medical institution code, designated retail drugstore code, medical insurance doctor code, medical insurance nurse code, medical service items Classes and codes, chronic diseases catalogue of medical insurance, settlement catalogue of medical insurance by diseases and daytime operation diseases catalogue of medical insurance will start to establish codes and catalogues for a total of 13 businesses, which will be fully informationized, and a medical insurance settlement list will be established on the basis of 13 codes and catalogues This document of the state health insurance bureau directly brings the medical and pharmaceutical industries from the industrialization era to the era of information and industry standardization, and builds a big data platform Under this big data platform, not only all-round supervision has become possible, but also the standardization of medical diagnosis and treatment, as well as the standardization and equivalence of medical security can be realized The impact on medicine and medical industry is subversive, which means that a new era of medicine industry is officially opened, the whole pharmaceutical industry chain will usher in change, some industries will usher in the spring of development, some industries will bid farewell to the stage completely The "vaccine law" of the industry was officially implemented on December 1 The tragedy will never happen again On the afternoon of June 29, the 11th meeting of the Standing Committee of the 13th National People's Congress voted to adopt the "vaccine management law of the people's Republic of China" In the bill, it clearly stipulates that the State supports the basic research and applied research of vaccines, formulates the development plan and industrial policies of vaccine industry, supports the development and structural optimization of vaccine industry, encourages the large-scale and intensive production of vaccines, formulates relevant development plans, arranges necessary funds, supports the development of new vaccines such as multi linked multi price vaccines, and encourages the holders of vaccine marketing licenses The drug regulatory department under the State Council, together with the health department under the State Council, shall establish a unified vaccine traceability standard, establish a collaborative platform for vaccine information traceability throughout the country, and provide severe penalties for illegal vaccine crimes, And make it clear that the criminal responsibility for vaccine crimes shall be investigated in accordance with the law With the deepening of anti-corruption of medicine, bribery will be out of business Recently, Jiangsu health and Health Commission issued the measures for the management of bad records of commercial bribery in the field of medicine purchase and sale in Jiangsu Province, which made it clear that as long as there was a commercial bribery of pharmaceutical enterprises within two years, all signed purchase and sale contracts would be terminated immediately, and no procurement in Jiangsu would be allowed within two years That is to say, all products of the enterprise will be kicked out of Jiangsu hospital market for two years Of course, not only in Jiangsu, but also under the pressure of medical anti-corruption, the inspection and punishment of commercial bribery in the field of medical purchase and sale are gradually increasing At present, most of the provinces in the country have new anti-commercial bribery documents, and even some provinces employ special personnel to visit medical institutions and pharmaceutical enterprises to investigate the situation of medical bribery Therefore, in the work of the enterprise, especially the leadership of the company relying on "rebate volume", it is necessary to pay attention to the compliance operation and avoid risks in the daily work in the future, and it is also necessary to make all pharmaceutical enterprises pay attention to it Otherwise, once the national policy is implemented, it is the end of the enterprise On July 3, Yunnan food and Drug Administration announced the notice of "opinions on further promoting the healthy development of drug retail enterprises" (hereinafter referred to as "opinions") According to the announcement, the opinions have been adopted at the 7th bureau meeting of Yunnan drug administration on June 21, 2019, and are hereby promulgated and shall come into force as of August 5, 2019 In the opinion, the government should actively guide and encourage the drug retail chain enterprises to carry out the long-distance pharmaceutical service and long-distance examination business of licensed pharmacists At the same time, according to the guiding principles of Yunnan Province Drug retail chain enterprise remote pharmaceutical service and review system (hereinafter referred to as the guiding principles), drug retail chain enterprises that carry out licensed pharmacist remote pharmaceutical service and review business may no longer have licensed pharmacists in their chain stores, but at least one legally qualified pharmaceutical technician shall be assigned as the quality responsibility People, to carry out pharmaceutical services The guiding principles also requires that at least three licensed pharmacists should be assigned to 10 base stores of drug retail chain enterprises, and one licensed pharmacist should be assigned to every 15 additional stores, and it is clearly mentioned to implement the classified and hierarchical management system of drug retail enterprises On July 1, Huaren pharmaceutical once again changed its ownership Huaren pharmaceutical announced that its controlling shareholder, Yongyu Hengfeng investment and its wholly-owned subsidiary, Yongyu Hengfeng investment management company, agreed to transfer 20% of the company's equity to Xi'an Qujiang culture and Finance Holding Co., Ltd After the completion of the transaction, Tianshui dahealth will become the controlling shareholder of Huaren pharmaceutical, and the Management Committee of Xi'an Qujiang New Area behind Qujiang financial holding will become the actual controller of the company; while Yongyu Hengfeng investment will no longer hold Huaren pharmaceutical shares, and the proportion of shares held by Yongyu Hengfeng investment in the total share capital of the listed company will become 6.66% In fact, this is the second change of ownership of Huaren pharmaceutical in three years In July 2016, Yongyu Hengfeng investment and its subsidiary Yongyu Hengfeng Investment Management Co., Ltd agreed to transfer 26.46% shares of Huaren Pharmaceutical Co., Ltd from Huaren century group at a price of 9.53 yuan / share, with a total transfer price of 1.658 billion yuan Whether the transfer can turn the tide is really unknown The new chairman and new officer of Taiji group took office They are looking forward to achieving the goal On July 4, Chongqing Taiji Group issued a notice that at the 17th meeting of the 9th board of directors, the board of directors agreed to elect Mr Li Yangchun as the chairman of the 9th board of directors of the company, whose term of office will expire on the expiration of the 9th board of directors of the company, that is, May 10, 2021 Li Yangchun was born in 1963 He is a senior economist and master of business administration at the International Open University of Asia (Macao) He joined Chongqing TongJunGe pharmaceutical factory in 1986 and Fuling pharmaceutical factory in 1989 He used to be the assistant of supply and marketing section chief and sales department manager of Fuling pharmaceutical factory, mainly engaged in sales Whether he can achieve the goal of "100 billion Tai Chi" within 10 years after taking office remains to be tested Information source: pharmaceutical economic news, Xinhuanet, Sina pharmaceutical, cyberblue, Chinanet, e pharmaceutical manager, interesting academic statement: this view only represents the author and does not represent the position of yaozhinet You are welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.